Enhancement of drug sensitivity via molecular therapies targeting tumor growth and antitumor immunity

The enhancement of drug sensitivity via molecular therapies targeting tumor growth and antitumor immunity. Human epidermal growth factor receptor (HER) 2- and HER3-targeted antibody–drug conjugate (ADC) products, including topoisomerase I (Topo I) inhibitors such as trastuzumab deluxecan (T-DXd) and patritumab deluxecan (HER3-DXd), have considerable antitumor effects in patients who have undergone HER2-targeted therapy. These ADCs are internalized into cancer cells and release Topo I inhibitors that are not cross-resistant to anthracyclines and taxanes, leading to cell death. The released payload penetrates adjacent cancer cells through a bystander effect. The ADC sacituzumab govitecan targets trophoblast antigen 2 (Trop-2), a surface protein bound to the Topo I inhibitor SN-38, which is released intracellularly and extracellularly. Cell cycle inhibitors targeting cyclin-dependent kinase 4/6 (CDK4/6) in the G1–S phase transition have shown promise when used in combination with endocrine therapy for patients with hormone receptor (HR)-positive HER2-negative breast cancer. The development of cancer stem cells (CSCs) with persisting drug resistance is a major obstacle in chemotherapy. CSC-targeting therapies, which target several signaling pathways involved in cancer survival, may be employed effectively in combination with conventional therapy to eradicate residual tumor cells for the curing of cancer. The combined use of anticancer drugs and immune checkpoint inhibitors, such as anti-programmed cell death 1 (PD-1), anti-programed cell death ligand 1 (PD-L1), and anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibodies, enhances therapeutic efficacy by increasing antitumor immune activity. Abbreviations: MHC, major histocompatibility complex; TCR, T-cell receptor; APC, antigen-presenting cell. This figure was custom-made by Wiley Editing Services based on our freehand drawing
Enhancement of drug sensitivity via molecular therapies targeting tumor growth and antitumor immunity

Publication

Impact of Complex Apoptotic Signaling Pathways on Cancer Cell Sensitivity to Therapy (2024) Ryungsa Kim, et al. Cancers (Basel). 2024 Mar;16(5). Figure: F6.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates CD80/86 CD86 ncbigene_symbol CD86 942
Homo sapiens Primates CD80/86 CD80 ncbigene_symbol CD80 941
Homo sapiens Primates MHC MHC ncbigene_synonym HLA-C 3107
Homo sapiens Primates TCR TCR ncbigene_synonym TRBV20OR9-2 6962
Homo sapiens Primates TCR TCR famplex_relations TRA 6955
Homo sapiens Primates TCR TCR famplex_relations TRB 6957
Homo sapiens Primates TCR TCR famplex_relations TRD 6964
Homo sapiens Primates TCR TCR famplex_relations TRG 6965
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym PDCD1 5133
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17 6139
Homo sapiens Primates PD-1 PD-1 ncbigene_synonym RPL17-C18orf32 100526842
Homo sapiens Primates CDK4/6 CDK4 ncbigene_symbol CDK4 1019
Homo sapiens Primates CDK4/6 CDK6 ncbigene_symbol CDK6 1021
Homo sapiens Primates HER2 HER2 ncbigene_synonym ERBB2 2064
Homo sapiens Primates HER3 HER3 ncbigene_synonym ERBB3 2065
Homo sapiens Primates Trop2 TROP2 ncbigene_synonym TACSTD2 4070
Homo sapiens Primates PD-L1 PD-L1 ncbigene_synonym CD274 29126
Homo sapiens Primates Wnt WNT famplex_relations WNT1 7471
Homo sapiens Primates Wnt WNT famplex_relations WNT2 7472
Homo sapiens Primates Wnt WNT famplex_relations WNT2B 7482
Homo sapiens Primates Wnt WNT famplex_relations WNT3 7473
Homo sapiens Primates Wnt WNT famplex_relations WNT3A 89780
Homo sapiens Primates Wnt WNT famplex_relations WNT4 54361
Homo sapiens Primates Wnt WNT famplex_relations WNT6 7475
Homo sapiens Primates Wnt WNT famplex_relations WNT7A 7476
Homo sapiens Primates Wnt WNT famplex_relations WNT7B 7477
Homo sapiens Primates Wnt WNT famplex_relations WNT8A 7478
Homo sapiens Primates Wnt WNT famplex_relations WNT8B 7479
Homo sapiens Primates Wnt WNT famplex_relations WNT9A 7483
Homo sapiens Primates Wnt WNT famplex_relations WNT9B 7484
Homo sapiens Primates Wnt WNT famplex_relations WNT10A 80326
Homo sapiens Primates Wnt WNT famplex_relations WNT10B 7480
Homo sapiens Primates Wnt WNT famplex_relations WNT11 7481
Homo sapiens Primates Wnt WNT famplex_relations WNT16 51384
Homo sapiens Primates Wnt WNT famplex_relations WNT5A 7474
Homo sapiens Primates Wnt WNT famplex_relations WNT5B 81029
Homo sapiens Primates Hedgehog HEDGEHOG famplex_relations DHH 50846
Homo sapiens Primates Hedgehog HEDGEHOG famplex_relations IHH 3549
Homo sapiens Primates Hedgehog HEDGEHOG famplex_relations SHH 6469
Homo sapiens Primates Notch NOTCH famplex_relations NOTCH1 4851
Homo sapiens Primates Notch NOTCH famplex_relations NOTCH2 4853
Homo sapiens Primates Notch NOTCH famplex_relations NOTCH3 4854
Homo sapiens Primates Notch NOTCH famplex_relations NOTCH4 4855

Chemical mentions

Word Match MeSH Name ChEBI
inhibitors inhibitors inhibitor chebi:35222
Nucleus nucleus nucleus chebi:33252

Disease mentions

Word Match MeSH Name DOID
cancer cancer cancer DOID:162
Cancer cancer cancer DOID:162